About AllergoPharma
AllergoPharma is a Healthcare company based in Reinbek (Germany) founded in 1969, and was acquired by Dermapharm in February 2020. It operates as an allergen immunotherapies for IgE-mediated diseases are developed by AllergoPharma. The company has 5,990 employees. Its focus areas include Life Sciences, Immunology, Drugs and Allergies. Its legal entity in India is Allergopharma India Private Limited (U21002DL2024FTC426111). Its competitors include BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Stallergenes Greer and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
AllergoPharma was founded in 1969 in Reinbek, Germany, as a specialty pharmaceutical company focused on allergen immunotherapies. As a subsidiary of Merck, causal treatments for IgE-mediated allergic diseases are developed, including subcutaneous options for unavoidable allergens such as pollen and dust mites. Operations center on advancing therapies for respiratory and other allergies in the European market.
- Headquarters Reinbek, Germany
- Employees 5,990
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website allergopharma.com
- Social LinkedIn X
- Acquired by Dermapharm (Feb 2020)
- Legal Name Allergopharma India Private Limited
- Date of Incorporation 02 Feb, 2024
- Jurisdiction New Delhi, Delhi, India
- Investors
- Employee Count5,990
- Acquired byDermapharm
(Feb 2020)
Associated legal entities of AllergoPharma
AllergoPharma operates through Allergopharma India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Allergopharma India Private Limited CIN U21002DL2024FTC426111 | Active | 02 Feb 2024 | New Delhi, Delhi | – | – | 2 | View details |
Investors in AllergoPharma
AllergoPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Dermapharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Dermatological and pharmaceutical medications are developed and manufactured. | 1991 | dermapharm.de | Grunwald, Germany |
Investor details for AllergoPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Allergopharma India Private Limited (AllergoPharma)
Allergopharma India Private Limited is the primary company behind AllergoPharma. The board of Allergopharma India Private Limited currently have 2 directors; the longest-serving is Vivek Narang, appointed in 2024. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vivek Narang DIN 10489460 | Non- Individual Subscriber | 02 Feb 2024 | 2 yrs 8 mo | Allergopharma India Private Limited |
| Dr Christoph Paul Josef Willers DIN 10489461 | Director | 02 Feb 2024 | 2 yrs 8 mo | Allergopharma India Private Limited |
Timeline of AllergoPharma
2 dated milestones of AllergoPharma across 51 years, from founding to its latest funding, stage changes and deals.
- Founded AllergoPharma is founded.
- Exit Acquired by Dermapharm.
Competitors of AllergoPharma
AllergoPharma has 9 listed competitors in our database, 6 of them funded. They include BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Stallergenes Greer, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| biontech.com | 2008 | Mainz, Germany | $805.99M | 4,530 | Immunotherapeutics for cancer and other diseases are developed. | |
| stallergenesgreer.com | 2013 | London, United Kingdom | – | 115,499 | Allergen immunotherapies for respiratory allergies are developed. | |
| decibeltx.com | 2015 | Cambridge, United States | $169.53M | 62 | Medicines are developed to protect, repair, and restore hearing capacity. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| sorrentotherapeutics.com | 1989 | San Diego, United States | – | 949 | Immuno therapeutics for cancer, inflammation, and autoimmune diseases are developed. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. |
Detailed competitors of AllergoPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as AllergoPharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allergopharma
Complete news archive for AllergoPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AllergoPharma
AllergoPharma was founded in 1969.
AllergoPharma is headquartered in Reinbek, Germany. It is registered at Reinbek, Schleswig-holstein, Germany.
AllergoPharma has 5,990 employees.
AllergoPharma was founded in 1969 in Reinbek, Germany, as a specialty pharmaceutical company focused on allergen immunotherapies. As a subsidiary of Merck, causal treatments for IgE-mediated allergic diseases are developed, including subcutaneous options for unavoidable allergens such as pollen and dust mites. Operations center on advancing therapies for respiratory and other allergies in the European market.
AllergoPharma's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
AllergoPharma has 1 investor. Key investors include Dermapharm.
AllergoPharma operates through Allergopharma India Private Limited.
Yes. AllergoPharma was acquired by Dermapharm in February 2020.
The legal entities of AllergoPharma currently have 2 directors, including Vivek Narang, Dr Christoph Paul Josef Willers.